More Videos
SPECIAL REPORT
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- S&P Stocks Trading at New 52-Week Highs
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Oil Price to Average $75.40 in 2010: Poll
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Jobless Claims Below 500,000, Durable Orders Slip
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Judge Erases Couple's $525,000 Mortgage Payment
- Black Friday: Can Banks Tap the Frenzy, Too?
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Treasury On Mortgage Modifications
- 'Cancer of Fraud' Permeates Health Care System: Critics
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Judge Erases Couple's $525,000 Mortgage Payment
- Where Do Pardoned Turkeys Go?
- Foreign Demand Boosts US 7-Year Treasury Sale
- Google CEO Schmidt Makes Secret Visit to Iraq
- New-Home Sales Jump to Highest Level in Over a Year
- Consumers Catching the Holiday Spirit
- Jobless Claims Below 500,000, Durable Orders Slip
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
But there's not much I can do about it. There's a limited amount of airtime on CNBC and whether it's biotech or any other sector, management draws the line on the market cap of companies that we'll highlight. But there are exceptions to the rule. And today there's an example.
Prana Biotechnology [PRAN
Loading...
()
] started out the trading day in the U.S. with a market value of about $75 million. On relatively heavy volume--as I write this--it's crossed the $100 million threshold. Typically not a company I'd be permitted to spend any time covering. But here's why I was able to "sell" what in TV-news lingo we call a "hit" (approximately one minute or the equivalent of maybe two inches of copy in a newspaper) to the producers of "Squawk on the Street" this morning: (You can watch it in the video clip.)
A. It's Alzheimer's Disease, a burgeoning epidemic that affects a lot of viewers.
B. The mostly positive results are from a mid-stage test. That increases the likelihood in today's environment that a pipeline-poor, cash-rich big drug company might come along and partner with or take out the company which doesn't have the money to pay for a large, late-stage clinical trial.
To PR folks who might be reading this, please don't interpret the coverage as setting any kind of precedent and start flooding my inbox or voicemail with a bunch of micro-cap pitches. This was a one-and-done report. In other words, I'm not doing the story on any other CNBC shows today with the exception, of course, of writing about it on this blog. And editorial decisions are made on a case by case basis.
Prana is sanskrit for life force. Namaste.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes